Immupharma Plc - Company Profile
Powered by 
All the data and insights you need on Immupharma Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Immupharma Plc Strategy Report
- Understand Immupharma Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
ImmuPharma Plc (ImmuPharma) is a biopharmaceutical company that focuses on discovery and development of peptide-based therapeutics for the treatment of serious medical conditions with unmet medical need. ImmuPharma develops drugs for the treatment of lupus, cancer, highly resistant hospital-acquired infections such as methicillin-resistant staphylococcus aureus infection. The company’s product pipeline comprises Lupuzor, for the treatment of Lupus; BioCIN, for treatment of methicillin-resistant Staphylococcus aureus; BioGlucagon for treatment of diabetes and P140, a drug developed for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. It has operations in France and Switzerland. ImmuPharma is headquartered in London, Greater London, the UK.
Headquarters
United Kingdom
Address
One Bartholomew Close, London, England, EC1A7BL
Website
www.immupharma.co.uk
Telephone
44 20 71524080
No of Employees
13
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IMM (LON)
EPS
XYZ
Net Income (2021)
XYZ
53.4%
(2021 vs 2020)
Market Cap*
$12.3M
Net Profit Margin (2020)
XYZ
-27.5%
(2021 vs 2020)
* As of and is in US$
Immupharma Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Urelix |
| Lupuzor (P140 or Forigerimod)- Lupus | Lupuzor |
| IIP-203101- Methicillin-Resistant Staphylococcus Aureus (MRSA) | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In March, the company signed a collaboration agreement with Orano SA to identify suitable radiotherapy candidates for the treatment of cancer. |
| 2021 | Contracts/Agreements | In November, the company announced collaboration with Imperial College London for providing intellectual input for a number of peptide assets under development |
| 2020 | Financing Agreements | In June, L1 Capital Global Opportunities Master Fund and Lind Global Macro Fund LP announced their plans to invest upto GBP4.94 million in the company. |
Competitor Comparison
| Key Parameters | Immupharma Plc | Alcon Laboratories (UK) Ltd | Allergan Ltd. | Neurocentrx Pharma Ltd | Sareum Holdings Plc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United Kingdom | United Kingdom |
| City | London | Camberley | Marlow | Edinburgh | Cambridge |
| State/Province | England | Surrey | England | Scotland | Cambridgeshire |
| No. of Employees | 13 | - | - | 2 | 5 |
| Entity Type | Public | Private | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tim McCarthy | Chairman; Chief Executive Officer | Executive Board | 2021 | - |
| Tim Franklin | Chief Operating Officer; Director | Executive Board | 2021 | - |
| Ewa Flynn | Chief Financial Officer; Secretary | Senior Management | 2021 | - |
| Laura Mauran-Ambrosino | Chief Scientific Officer - ImmuPharma Biotech | Senior Management | - | - |
| Sebastien Goudreau | Director | Non Executive Board | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer